Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone.

Treatment of gonorrhoea is threatened by antimicrobial resistance, and decreased susceptibility and resistance to recommended therapies is emerging in Europe. Current associations between resistance and molecular type remain poorly understood. Gonococcal isolates (n=1,066) collected for the 2009 and 2010 European Gonococcal Antimicrobial Surveillance Programme were typed by Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST). A total of 406 sequence types (STs) were identified, 125 of which occurred in ≥two isolates. Seven major genogroups of closely related STs (varying by ≤1% at just one of the two target loci) were defined. Genogroup 1407 (G1407), observed in 20/21 countries and predominant in 13/21 countries, accounted for 23% of all isolates and was associated with decreased susceptibility to cefixime and resistance to ciprofloxacin and raised minimum inhibitory concentrations for ceftriaxone and azithromycin. Genogroup 225 (G225), associated with ciprofloxacin resistance, was observed in 10% of isolates from 19/21 countries. None of the other genogroups were associated with antimicrobial resistance. The predominance of a multidrug-resistant clone (G1407) in Europe is worrying given the recent reports of recommended third generation cephalosporins failing to treat infections with this clone. Identifying associations between ST and antimicrobial resistance aids the understanding of the dissemination of resistant clones within a population and could facilitate development of targeted intervention strategies.

[1]  Kevin A Fenton,et al.  Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. , 2004, The Journal of infectious diseases.

[2]  B. Spratt,et al.  Changing epidemiologic profile of quinolone-resistant Neisseria gonorrhoeae in London. , 2005, The Journal of infectious diseases.

[3]  M. Unemo,et al.  Neisseria gonorrhoeae population in Arkhangelsk, Russia: phenotypic and genotypic heterogeneity. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  Kevin A Fenton,et al.  Geographical and demographic clustering of gonorrhoea in London , 2007, Sexually Transmitted Infections.

[5]  M. Unemo,et al.  The Neisseria gonorrhoeae population in Sweden during 2005—phenotypes, genotypes and antibiotic resistance , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[6]  H. Palmer,et al.  Prediction of antibiotic resistance using Neisseria gonorrhoeae multi-antigen sequence typing , 2008, Sexually Transmitted Infections.

[7]  M. Cusini,et al.  Erratum: Phenotypic and genotypic characterization of Neisseria gonorrhoeae in parts of Italy: Detection of a multiresistant cluster circulating in a heterosexual network (Clinical Microbiology and Infection (2008) vol. 14 (949-954)) , 2008 .

[8]  W. Wong,et al.  Molecular Epidemiological Identification of Neisseria gonorrhoeae Clonal Clusters with Distinct Susceptibility Profiles Associated with Specific Groups at High Risk of Contracting Human Immunodeficiency Virus and Syphilis , 2008, Journal of Clinical Microbiology.

[9]  I. Dal Conte,et al.  Phenotypic and genotypic characterization of Neisseria gonorrhoeae in parts of Italy: detection of a multiresistant cluster circulating in a heterosexual network. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  J. Jensen,et al.  2009 European (IUSTI/WHO) Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults , 2009, International journal of STD & AIDS.

[11]  H. Palmer,et al.  Gonococcal antibiotic surveillance in Scotland (GASS): prevalence, patterns and trends in 2008. , 2009 .

[12]  A. Limnios,et al.  Characteristics and Population Dynamics of Mosaic penA Allele-Containing Neisseria gonorrhoeae Isolates Collected in Sydney, Australia, in 2007-2008 , 2009, Antimicrobial Agents and Chemotherapy.

[13]  Jeffrey D. Klausner,et al.  Mosaic Penicillin-Binding Protein 2 in Neisseria gonorrhoeae Isolates Collected in 2008 in San Francisco, California , 2009, Antimicrobial Agents and Chemotherapy.

[14]  M. Yen,et al.  Characteristics and Dissemination of Mosaic Penicillin-Binding Protein 2-Harboring Multidrug-Resistant Neisseria gonorrhoeae Isolates with Reduced Cephalosporin Susceptibility in Northern Taiwan , 2010, Antimicrobial Agents and Chemotherapy.

[15]  Márcia Boura,et al.  Genotypes and antimicrobial-resistant phenotypes of Neisseria gonorrhoeae in Portugal (2004–2009) , 2010, Sexually Transmitted Infections.

[16]  D. Lewis The Gonococcus fights back: is this time a knock out? , 2010, Sexually Transmitted Infections.

[17]  M. Unemo,et al.  Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  Kyungwon Lee,et al.  Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. , 2010, The Journal of antimicrobial chemotherapy.

[19]  M. Unemo,et al.  Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden , 2010, Sexually Transmitted Infections.

[20]  C. Lowndes,et al.  Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. , 2011, The Journal of antimicrobial chemotherapy.

[21]  Phenotypic and genotypic properties of Neisseria gonorrhoeae isolates in Norway in 2009: antimicrobial resistance warrants an immediate change in national management guidelines , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[22]  M. Unemo,et al.  Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[23]  M. Unemo,et al.  High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure , 2011, Antimicrobial Agents and Chemotherapy.

[24]  M. Unemo,et al.  Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone , 2011, Antimicrobial Agents and Chemotherapy.

[25]  Y. Koga,et al.  Antibiotic-Resistant Phenotypes and Genotypes of Neisseria gonorrhoeae Isolates in Japan: Identification of Strain Clusters With Multidrug-Resistant Phenotypes , 2011, Sexually transmitted diseases.

[26]  G. Horsman,et al.  Influence of Conserved and Hypervariable Genetic Markers on Genotyping Circulating Strains of Neisseria gonorrhoeae , 2011, PloS one.

[27]  M. Unemo,et al.  An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. , 2011, The Journal of antimicrobial chemotherapy.

[28]  A Stary,et al.  First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[29]  J. Dillon,et al.  Analysis of mutations in multiple loci of Neisseria gonorrhoeae isolates reveals effects of PIB, PBP2 and MtrR on reduced susceptibility to ceftriaxone. , 2011, The Journal of antimicrobial chemotherapy.

[30]  K. Sankar,et al.  Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[31]  M. Unemo,et al.  Genome Sequencing of a Neisseria gonorrhoeae Isolate of a Successful International Clone with Decreased Susceptibility and Resistance to Extended-Spectrum Cephalosporins , 2012, Antimicrobial Agents and Chemotherapy.

[32]  M. Gilmour,et al.  Emergence and Characterization of Neisseria gonorrhoeae Isolates With Decreased Susceptibilities to Ceftriaxone and Cefixime in Canada: 2001–2010 , 2012, Sexually transmitted diseases.

[33]  I. Dal Conte,et al.  Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoeae in Italy from 2006 to 2010. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  Jeffrey D Klausner,et al.  Using the Neisseria gonorrhoeae multiantigen sequence-typing method to assess strain diversity and antibiotic resistance in San Francisco, California. , 2012, Microbial drug resistance.

[35]  J. Lo,et al.  Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. , 2012, The Journal of antimicrobial chemotherapy.

[36]  M. Unemo,et al.  Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[37]  M. Unemo,et al.  2012 European guideline on the diagnosis and treatment of gonorrhoea in adults , 2013, International journal of STD & AIDS.

[38]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).